Ursodiol ( DrugBank: Ursodiol )

6 diseases

8. ハンチントン病

臨床試験数 : 242 / 薬物数 : 205 - (DrugBank : 62) / 標的遺伝子数 : 85 - 標的パスウェイ数 : 159

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00514774 (ClinicalTrials.gov)	August 2007	8/8/2007	Ursodiol in Huntington's Disease	Ursodiol in Huntington's Disease	Huntington Disease	Drug: ursodiol;Drug: placebo	Oregon Health and Science University	Huntington Study Group;Huntington Society of Canada	Active, not recruiting	18 Years	N/A	Both	21	Phase 1	United States

臨床試験数 : 61 / 薬物数 : 90 - (DrugBank : 31) / 標的遺伝子数 : 23 - 標的パスウェイ数 : 126

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00004442 (ClinicalTrials.gov)	September 1997	18/10/1999	Study of Bile Acids in Patients With Peroxisomal Disorders		Infantile Refsum's Disease;Zellweger Syndrome;Bifunctional Enzyme Deficiency;Adrenoleukodystrophy	Drug: chenodeoxycholic acid;Drug: cholic acid;Drug: ursodiol	Children's Hospital Research Foundation University of Cincinnati	Children's Hospital Medical Center, Cincinnati	Terminated	N/A	5 Years	Both	25	N/A	NULL

臨床試験数 : 298 / 薬物数 : 252 - (DrugBank : 59) / 標的遺伝子数 : 35 - 標的パスウェイ数 : 115

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00004784 (ClinicalTrials.gov)	January 1994	24/2/2000	Phase III Randomized Study of Ursodiol With Vs Without Methotrexate for Primary Biliary Cirrhosis		Liver Cirrhosis, Biliary	Drug: methotrexate;Drug: ursodiol	National Center for Research Resources (NCRR)	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK);University of Texas	Completed	20 Years	69 Years	Both	315	Phase 3	NULL
2	NCT00006168 (ClinicalTrials.gov)	January 1994	8/8/2000	Ursodiol-Methotrexate for Primary Biliary Cirrhosis		Liver Cirrhosis, Biliary	Drug: Methotrexate	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	NULL	Completed	20 Years	69 Years	Both		Phase 3	United States
3	NCT00004748 (ClinicalTrials.gov)	November 1989	24/2/2000	Low-Dose Oral Methotrexate Versus Colchicine for Primary Biliary Cirrhosis	Phase III Randomized, Double-Blind, Placebo-Controlled Study of Low-Dose Oral Methotrexate Versus Colchicine for Primary Biliary Cirrhosis	Liver Cirrhosis, Biliary	Drug: colchicine;Drug: methotrexate;Drug: ursodiol	National Center for Research Resources (NCRR)	Tufts Medical Center	Completed	N/A	N/A	Both	90	Phase 3	NULL

臨床試験数 : 2,630 / 薬物数 : 1,459 - (DrugBank : 265) / 標的遺伝子数 : 144 - 標的パスウェイ数 : 202

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03724175 (ClinicalTrials.gov)	August 26, 2019	12/10/2018	The Role of Secondary Bile Acids in Intestinal Inflammation	The Role of Secondary Bile Acids in Intestinal Inflammation	Ulcerative Colitis;Pouchitis	Drug: ursodiol (ursodeoxycholic acid, UDCA)	Stanford University	NULL	Recruiting	18 Years	70 Years	All	15	Phase 2/Phase 3	United States

臨床試験数 : 39 / 薬物数 : 35 - (DrugBank : 12) / 標的遺伝子数 : 13 - 標的パスウェイ数 : 45

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00004442 (ClinicalTrials.gov)	September 1997	18/10/1999	Study of Bile Acids in Patients With Peroxisomal Disorders		Infantile Refsum's Disease;Zellweger Syndrome;Bifunctional Enzyme Deficiency;Adrenoleukodystrophy	Drug: chenodeoxycholic acid;Drug: cholic acid;Drug: ursodiol	Children's Hospital Research Foundation University of Cincinnati	Children's Hospital Medical Center, Cincinnati	Terminated	N/A	5 Years	Both	25	N/A	NULL

臨床試験数 : 1,695 / 薬物数 : 1,527 - (DrugBank : 268) / 標的遺伝子数 : 111 - 標的パスウェイ数 : 174

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00004441 (ClinicalTrials.gov)	September 1997	18/10/1999	Study of Tauroursodeoxycholic Acid for Hepatobiliary Disease in Cystic Fibrosis		Cystic Fibrosis	Drug: tauroursodeoxycholic acid;Drug: ursodiol	Children's Hospital Medical Center, Cincinnati	NULL	Completed	N/A	N/A	Both	39	N/A	United States;Italy
2	NCT00004315 (ClinicalTrials.gov)	November 1995	18/10/1999	Phase II Pilot Study to Compare the Bioavailability of Buffered, Enteric-Coated Ursodiol With Unmodified Ursodiol for Chronic Cholestatic Liver Disease and Cystic Fibrosis-Associated Liver Disease		Cystic Fibrosis;Gastrointestinal Diseases;Cholestasis	Drug: ursodiol	National Center for Research Resources (NCRR)	Children's Hospital Medical Center, Cincinnati	Active, not recruiting	4 Months	N/A	Both	20	Phase 2	United States